RELATIONSHIP OF Concentration and Response Dr. Mohd Bin Makmor Bakry, PhD, RPh Senior Lecturer in Clinical Pharmacy Intensive Care Preceptor Universiti.

Slides:



Advertisements
Similar presentations
Instant Clinical Pharmacology E.J. Begg
Advertisements

First, zero, pseudo-zero order elimination Clearance
PHARMACOKINETIC.
DISPOSITION OF DRUGS The disposition of chemicals entering the body (from C.D. Klaassen, Casarett and Doull’s Toxicology, 5th ed., New York: McGraw-Hill,
Module 2 # 2 Pharmacokinetics absorption of drugs drugs can be given iv, im, sc, orally (po) if given parenterally, they should.
Dosage Regimen Design in Patients with Renal Insufficiency Cont’d Pharmacy 732 Winter, 2001.
Pharmacotherapy in the Elderly Judy Wong
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
Pharmacokinetics (PK): What the body does to the drug? Most drugs: Enter the body by crossing barriers Distributed by the blood to the site of action Biotransform.
Dose Adjustment in Renal and Hepatic Disease
Pharmacology Department
Excretion of Drugs By the end of this lecture, students should be able to Identify main and minor routes of Excretion including renal elimination and biliary.
Is the passage of drug from its site of administration to its site of action through cell membranes. Sites of Administration Sites of action Cell membrane.
CLEARANCE (CL) describes the efficiency of irreversible elimination of a drug from the body by excretion of unchanged drug. Metabolic conversion of the.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 4 Pharmacokinetics.
Prof. Hanan Hagar Pharmacology Department.  Is the fraction of unchanged drug that enters systemic circulation after administration and becomes available.
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
PHARMACOKINETICS 1. Fate of drugs in the body 1.1 absorption
Nonlinear Pharmacokinetics
Pharmacokinetics Introduction
Lecture 2.  Clearance Ability to eliminate the drug  Volume of distribution (Vd) The measure of the apparent space in the body available to contain.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
Pharmacology Department
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
Core Concepts in Pharmacology Chapter 5 Pharmacokinetics.
VARIABILITY IN PHARMACOKINETICS & PATIENT RESPONSE Dr. Mohd B. Makmor Bakry, Ph.D., RPh Senior Lecturer in Clinical Pharmacy Universiti Kebangsaan Malaysia.
Factoid: Is there a difference in blood flow (Q) between an athlete and non- athlete? Blood flow increases during exercise. At rest, blood flow is similar.
BASIC PRINCIPLES IN CLINICAL PHARMACOKINETICS Dr. Mohd Bin Makmor Bakry, PhD, RPh Senior Lecturer in Clinical Pharmacy Intensive Care Preceptor Faculty.
NON LINEAR PHARMACOKINETICS Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas 2013.
1. Fate of drugs in the body 1.1 absorption 1.2 distribution - volume of distribution 1.3 elimination - clearance 2. The half-life and its uses 3. Repeated.
Pharmacology Department
Excretion of Drugs By the end of this lecture, students should be able to Identify main and minor routes of Excretion including renal elimination and biliary.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.
Pharmacology Department
TDM Therapeutic Drug Monitoring
Prof. Dr. Henny Lucida, Apt
Therapeutic drug Monitoring
Clinical Pharmacokinetics of PHENYTOIN & OTHER ANTIEPILEPTICS
Clinical Pharmacokinetic Equations and Calculations
DEFINITIONS T1/2 & Tmax Cmax AUC 1st order kinetics
Lecture 2 Clearance, maintenance dose and AUC
PHT 415 BASIC PHARMACOKINETICS
The General Concepts of Pharmacokinetics and Pharmacodynamics
Pharmacokinetics 2 General Pharmacology M212
415 PHT Plasma Level – Time Curve
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
Foundation Knowledge and Skills
DOSAGE ADJUSTMENT IN RENAL AND HEPATIC DISEASES Course Title : Biopharmaceutics and Pharmacokinetics – II Course Teacher : Zara Sheikh.
INTRODUCTION TO PHARMACOKINETICS M. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague, Charles University in Prague,
By : Dr. Roshini Murugupillai
Immunology and immunodiagnostics
Clinical Pharmacokinetics of VANCOMYCIN
Pharmacokinetic Modeling (describing what happens)
Dosing Regimen Concepts: 2-C, MM, Individualization principles
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Anticonvulsants: Valproic acid
Quantitative Pharmacokinetics
Factors affecting Drug Activity
Pharmacokinetics & Drug Dosing
School of Pharmacy, University of Nizwa
Clinical Pharmacokinetics
Selected Bioavailability and Pharmacokinetic Calculations
1 Concentration-time curve
Basic Biopharmaceutics
School of Pharmacy, University of Nizwa
Therapeutic Drug Monitoring chapter 1 part 1
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

RELATIONSHIP OF Concentration and Response Dr. Mohd Bin Makmor Bakry, PhD, RPh Senior Lecturer in Clinical Pharmacy Intensive Care Preceptor Universiti Kebangsaan Malaysia Kuala Lumpur

FACTORS THAT INFLUENCE DRUG CONCENTRATION  Drug administration –Dose Increase in dose will increase the drug concentration.Increase in dose will increase the drug concentration. –Interval The shorter the duration the higher the concentration.The shorter the duration the higher the concentration. –Route of administration Intravenous is superior than oralIntravenous is superior than oral

FACTORS THAT INFLUENCE DRUG CONCENTRATION (CONT’)  Absorption –The bioavailability Route of administrationRoute of administration –The salt factor Percentage of pure active compound in the salt.Percentage of pure active compound in the salt. eg.: PHT Na = 0.92, THP = 0.8 x Aminophyllineeg.: PHT Na = 0.92, THP = 0.8 x Aminophylline –Absorption sites The gut functionThe gut function –Short gut syndrome, post gastectomy Muscular pHMuscular pH –Myositis (acidic pH) Blood flowBlood flow Drug interactionsDrug interactions

FACTORS THAT INFLUENCE DRUG CONCENTRATION (CONT’)  Distribution –The volume of distribution Increase in volume (body water) may reduce hydrophilic drug concentration.Increase in volume (body water) may reduce hydrophilic drug concentration. Third space lost, large amount of water accumulate outside the tissue.Third space lost, large amount of water accumulate outside the tissue. –eg.: ascites, bullae and vesicle –Compartment model 2 compartment model, early administration Cp will be high, after distribution completed the Cp will be reduced. eg. DGX2 compartment model, early administration Cp will be high, after distribution completed the Cp will be reduced. eg. DGX –Drug interactions Depletion from protein binding. eg. PHT with PhenylbutazoneDepletion from protein binding. eg. PHT with Phenylbutazone

FACTORS THAT INFLUENCE DRUG CONCENTRATION (CONT’)  Metabolism –Inducers and inhibitors –Liver function  Excretion –Liver and kidney functions –Drug interactions Urinary acidifier, eg. Na phosphate, NH 4 Cl, H 2 CO 3Urinary acidifier, eg. Na phosphate, NH 4 Cl, H 2 CO 3 Urinary alkalizer, eg. Na citrate, ascorbic acidUrinary alkalizer, eg. Na citrate, ascorbic acid Renal blood flow adjuster, eg. NSAIDsRenal blood flow adjuster, eg. NSAIDs

DRUG CONCENTRATION TERMS Cp % of population who response 50 a a b b Cp ECLC ? Subtherapeutic Therapeutic ? Toxic

CONCENTRATION-RESPONSE RELATIONSHIP FOR SPECIFIC DRUG  Gentamicin Response rate (%) Maximum peak Cp : MIC

 Digoxin CONCENTRATION-RESPONSE RELATIONSHIP FOR SPECIFIC DRUG (CONT’) % change in ventricular rate from pretreatment Plasma DGX concentration

 Digoxin (cont’) Percentage of patient Plasma DGX concentration Non-toxicToxic CONCENTRATION-RESPONSE RELATIONSHIP FOR SPECIFIC DRUG (CONT’)

 Theophylline Theophylline Concentration Normalized improvement in FEV 1 CONCENTRATION-RESPONSE RELATIONSHIP FOR SPECIFIC DRUG (CONT’)

 Theophylline (cont’) Nausea InsomniaDiarrhea Persistent vomiting GI bleeding Seizures Cardiac arrhythmia ArrhythmiaSeizures Theophylline Concentration (  mol/L) CONCENTRATION-RESPONSE RELATIONSHIP FOR SPECIFIC DRUG (CONT’)

 Phenytoin t (months) Plasma PHT Concentration = seizure attack CONCENTRATION-RESPONSE RELATIONSHIP FOR SPECIFIC DRUG (CONT’)

 Phenytoin (cont’) Dose Plasma PHT Concentration INDIVIDUALIZATION CONCENTRATION-RESPONSE RELATIONSHIP FOR SPECIFIC DRUG (CONT’)

 Phenytoin (cont’) Plasma PHT Concentration Mental changes Nystagmus on 45° deviation Ataxia Nystagmus on far lateral CONCENTRATION-RESPONSE RELATIONSHIP FOR SPECIFIC DRUG (CONT’)

TARGET RANGE TERMS T P T = TroughP = Peak

THE TARGET RANGE  Aminoglycosides –Gentamicin/NetilmycinT <2 P 4-10 mg/L –AmikacinT <10 P mg/L  Vancomycin T P mg/L  Digoxin T mcg/L  Antiepileptics –PhenytoinT mg/L –CarbamazepineT 4-12 mg/L  Theophylline T mg/L  Ciclosporin A varies  Lithium T mEq/L  Phenobarbital T mg/L  Salicylates mg/L

SAMPLING GUIDELINES  DrugWhen to SampleIdeal time  AminoglycosidesP: 30 min post dose15 H T: just before the next dose  VancomycinP: 1H post 1H infusion24 H T: Just before the next dose  PhenytoinT: Just before the next dose5 – 14 D  CarbamazepineT: Just before the next dose7 – 12 D  Vaproic acidT: Just before the next dose4 D  Theophylline (PO) T: Just before the next dose2 D  Aminophylline(IV)18 – 24 H after starting or2 D changing a MD given as constant infusion  DigoxinT: Just before the next dose5 D (> 6 hours post dose)  Ciclosporin AC 2hour 17 – 40 H

THANK YOU